WO1993020847A1 - Vaccine adjuvant - Google Patents

Vaccine adjuvant Download PDF

Info

Publication number
WO1993020847A1
WO1993020847A1 PCT/US1993/003295 US9303295W WO9320847A1 WO 1993020847 A1 WO1993020847 A1 WO 1993020847A1 US 9303295 W US9303295 W US 9303295W WO 9320847 A1 WO9320847 A1 WO 9320847A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
immunogen
group
phenyl
branched chain
Prior art date
Application number
PCT/US1993/003295
Other languages
English (en)
French (fr)
Inventor
Richard L. Miller
Mark A. Tomai
David I. Bernstein
Christopher J. Harrison
Original Assignee
Minnesota Mining And Manufacturing Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining And Manufacturing Company filed Critical Minnesota Mining And Manufacturing Company
Priority to AU40480/93A priority Critical patent/AU674313B2/en
Priority to KR1019940703651A priority patent/KR100263804B1/ko
Priority to NZ280098A priority patent/NZ280098A/en
Priority to JP51846793A priority patent/JP3732506B2/ja
Priority to DE69304521T priority patent/DE69304521T2/de
Priority to CA002118239A priority patent/CA2118239C/en
Priority to EP93911614A priority patent/EP0636031B1/en
Priority to HK98107214A priority patent/HK1007962A1/en
Publication of WO1993020847A1 publication Critical patent/WO1993020847A1/en
Priority to NO19943920A priority patent/NO313864B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Definitions

  • This invention relates to compositions comprising a vaccine and a vaccine adjuvant. In another aspect this invention relates to vaccine adjuvants.
  • vaccines possessing antigenic epitopes that were previously impossible to produce.
  • vaccine candidates include synthetic peptides mimicking streptococcal, gonococcal, and malarial antigens. These purified antigens are generally weak immunogens, however, that require adjuvants in order to evoke protective immunity.
  • conventional vaccine adjuvants possess a number of drawbacks which limit their overall use and effectiveness.
  • Staphylococcus enterotoxin B has not been found to be immunoenhancing for either cell- mediated (e.g., cytotoxic T-cell lymphocytes) or humoral immune responses (i.e., specific antibody production) even though the enterotoxin has been shown to increase the level of production of various cytokines such as IL-2, TNF, gamma-interferon, etc. (see, e.g., J. Immunol.. 1975, 115. 575 (Smith et al.) and Infection and Immunity.
  • cell- mediated e.g., cytotoxic T-cell lymphocytes
  • humoral immune responses i.e., specific antibody production
  • This invention provides an immunogen/vaccine adjuvant composition
  • an immunogen/vaccine adjuvant composition comprising an immunogen in an amount effective to stimulate an immune response and as a vaccine adjuvant a lH-imidazo[4,5-c]quinolin-4-amine in an amount effective to increase the immune response to the immunogen.
  • This invention also provides a method of increasing the immune response to an immunogen, comprising the step of administering (i) the immunogen in an amount effective to stimulate an immune response, and (ii) as a vaccine adjuvant a lH-imidazo[4,5-c]quinolin-4-amine in an amount effective to increase the immune response.
  • Certain lH-imidazo[4,5-c]quinolin-4-amines have been disclosed as antiviral agents (see, e.g., U.S. Pat. Nos. 4,689,338 (Gerster) and 4,929,624 (Gerster et al.), European Patent Application 90.301776.3 (Gerster) and commonly assigned copending U.S.
  • immunogen/vaccine adjuvant composition refers to a combination of an immunogen and a lH-imidazo[4,5-c]quinolin-4-amine, whether that combination is in the form of an admixture of the two components in a pharmaceutically acceptable carrier or in the form of separate, individual components, for example in the form of a kit comprising an immunogen as one component and the lH-imidazo[4,5- c]quinolin-4-amine as another component.
  • the vaccine adjuvant component of a composition of the invention is a lH-imidazo[4,5-c]quinolin-4-amine. It has been found that compounds of this class induce biosynthesis of a variety of cytokines in human and murine cells. While the particular profile of cytokine induction varies to some extent from compound to compound within this class, it is thought that the general profile of cytokine induction common to the compounds of the class is responsible for the vaccine adjuvant activity of the compounds. Also, some compounds of this class have been shown to be potent stimulants of ⁇ -lymphocytes and therefore capable of increasing humoral immune response.
  • lH-imidazo[4,5-c]quinolin-4-amine is a compound defined by one of Formulas I-V below:
  • R n is selected from the group consisting of alkyl, hydroxyalkyl, acyloxyalkyl, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than 6 carbon atoms;
  • R 21 is selected from the group consisting of hydrogen, alkyl of one to about eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by
  • R 12 is selected from the group consisting of straight chain or branched chain alkenyl containing 2 to about 10 carbon atoms and substituted straight chain or branched chain alkenyl containing 2 to about 10 carbon atoms, wherein the substituent is selected from the group consisting of straight chain or branched chain alkyl containing 1 to about 4 carbon atoms and cycloalkyl containing 3 to about 6 carbon atoms; and cycloalkyl containing 3 to about 6 carbon atoms substituted by straight chain or branched chain alkyl containing 1 to about 4 carbon atoms; and R 22 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain
  • 23 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl of one to about eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl) thyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl of one to about four carbon atoms, straight chain or branched chain alkoxy of one to about four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms; and each R 3 is independently selected from the group consisting of straight chain or branched chain alkoxy of one to about four carbon atoms, halogen, and straight chain or branched chain alkyl of one to about four carbon atoms, and n is an integer from zero to
  • R 14 is -CHR A R B wherein R B is hydrogen or a carbon-carbon bond, with the proviso that when R B is hydrogen R A is alkoxy of one to about four carbon atoms, hydroxyalkoxy of one to about four carbon atoms, 1-alkynyl of two to about ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when R B is a carbon-carbon bond R B and R A together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to about four carbon atoms;
  • R 24 is selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; and
  • R 4 is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to about four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to about four carbon atoms;
  • R 15 is selected from the group consisting of: hydrogen; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one
  • R x and R y are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is elected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen;
  • X is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, haloalkyl of one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, alkylthio of one to about four carbon atoms; and R 5 is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to about four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to about four carbon atoms; or a pharmaceutically acceptable salt of any of the foregoing.
  • n can be zero, one, or two, n is preferably zero or one.
  • the substituents R ⁇ s above are generally designated "benzo substituents" herein.
  • the preferred benzo substituent is hydrogen.
  • the substituents ⁇ -R ⁇ 5 above are generally designated "1-substituents" herein.
  • the preferred 1- substituent is 2-methylpropyl or 2-hydroxy-2-methylpropy1.
  • the substituents R 2 ⁇ -R 25 above are generally designated “2-substituents” herein.
  • the preferred 2- substituents are hydrogen, alkyl of one to about six carbon atoms , alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms. Most preferably the 2-substituent is hydrogen, methyl, or ethoxymethyl.
  • Preferred compounds lH-imidazo[4,5-c] quinolin-4- amines include: l-(2-methylpropyl)-lH-imidazo[4,5-c]quinolin-4- amine;
  • the lH-imidazo[4,5-c]quinolin-4-amine is present (or administered, as appropriate to the form of the immunogen/vaccine adjuvant composition) in an amount effective to increase the immune response to a particular immunogen.
  • the compound is administered independent of the immunogen, e.g., by separate injection, the compound is generally administered in an amount of about 0.003 to about 5 mg/kg.
  • the particular amount that constitutes an effective amount depends to some extent upon certain factors, including the particular lH-imidazo[4,5-c]quinolin-4-amine, the particular immunogen being administered and the amount thereof, the immune response that is to be enhanced (humoral or cell mediated), the state of the immune system (e.g., suppressed, compromised, stimulated) , the method and order of administration of the compound and the immunogen, the species, and the desired therapeutic result. Accordingly it is not practical to set forth generally the amount that constitutes an effective amount of the lH-imidazo[4,5-c]quinolin-4-amine. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.
  • the immunogen can be any material that raises either humoral or cell mediated immune response, or both.
  • Suitable immunogens include live viral and bacterial immunogens and inactivated viral, tumor-derived, protozoal, organism-derived, fungal, and bacterial immunogens, toxoids, toxins, polysaccharides, proteins, glycoproteins, peptides, and the like.
  • vaccine preparations such as those used in connection with BCG (live bacteria) , cholera, plague, and typhoid (killed bacteria) , hepatitis B, influenza, inactivated polio, and rabies (inactivated virus) , measles, mumps, rubella, oral polio and yellow fever (live virus) , tetanus and diphtheria (toxoids) , hemophilus influenzae b, meningococcal, and pneumococcal (bacterial polysaccharides) can be used as the immunogen.
  • BCG live bacteria
  • cholera cholera
  • plague plague
  • typhoid killed bacteria
  • hepatitis B influenza
  • influenza inactivated polio
  • rabies inactivated virus
  • measles measles
  • mumps rubella
  • oral polio and yellow fever live virus
  • tetanus and diphtheria toxoids
  • the lH-imidazo[4,5-c]quinolin- 4-amine compounds induce biosynthesis of antiviral cytokines, in the instance of a live viral immunogen it is preferred to administer the virus prior to administration of the adjuvant compound in order that the viral infection can be established.
  • Exemplary experimental subunit immunogens include those related to viral disease such as adenovirus, AIDS, chicken pox, cytomegalovirus, dengue, feline leukemia, fowl plague, hepatitis A, hepatitis B, HSV-1, HSV-2, hog cholera, influenza A, influenza B, Japanese encephalitis, measles, parainfluenza, rabies, respiratory syncytial virus, rotavirus, wart, and yellow fever.
  • viral disease such as adenovirus, AIDS, chicken pox, cytomegalovirus, dengue, feline leukemia, fowl plague, hepatitis A, hepatitis B, HSV-1, HSV-2, hog cholera, influenza A, influenza B, Japanese encephalitis, measles, parainfluenza, rabies, respiratory syncytial virus, rotavirus, wart, and yellow fever.
  • Preferred immunogens for use in this invention include T-dependent immunogens such as viral pathogens and tumor-derived immunogens.
  • a particular preferred immunogen for use in this invention is a herpes simplex II (HSV-2) glycoprotein subunit preparation prepared as described in J. Infect. Pis. 1987, 155, 914 (Stanberry et al.).
  • the immunogen is administered in an amount effective to stimulate an immune response.
  • the amount that constitutes an effective amount depends to some extent upon certain factors, including the particular immunogen, the particular adjuvant being administered and the amount thereof, the immune response that is to be enhanced (humoral or cell mediated) , the state of the immune system (e.g., suppressed, compromised, stimulated), the method and order of administration of the compound and the immunogen, and the desired therapeutic result. Accordingly it is not practical to set forth generally the amount that constitutes an effective amount of immunogen. Those of ordinary skill in the art, however, can readily determine the appropriate amount with due consideration of such factors.
  • immunogen/vaccine adjuvant compositions of the invention can contain further pharmaceutically acceptable ingredients, excipients, carriers, and the like well known to those skilled in the art.
  • the immunogen/vaccine adjuvant composition of the invention can be administered to animals, e.g., mammals (human and non-human) , fowl, and the like according to conventional methods well known to those skilled in the art (e.g., orally, subcutaneously, nasally, topically). It is preferred to administer the lH-imidazo[4,5-c]quinolin-4-amine simultaneously with the immunogen (together in admixture or separately, e.g., orally or by separate injection) or subsequent to challenge with the immunogen. As seen in the Examples that follow (and as is common in the art) administration of the vaccine adjuvant prior to challenge with the immunogen can result in immunosuppression rather than stimulation.
  • Compound A designates l-(2- methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine.
  • Compound B designates l-(2-hydroxy-2-methylpropyl)- lH-imidazo[4,5-c]quinolin-4-amine.
  • Compound C designates 1-(2-hydroxy-2-methylpropyl)-2-methyl-1H- imidazo[4,5-c]quinolin-4-amine.
  • Compound D designates 1-(2-hydroxy-2-methylpropyl)-2-ethoxymethyl- lH-imidazo[4,5-c]quinolin-4-amine.
  • PBMC Peripheral blood mononuclear cells
  • Ficoll-Paque® solution available from Pharmacia LKB Biotechnology Inc. , Piscataway, NJ
  • the PBMC are washed with Hank's Balanced Salts Solution then diluted with RPMI 1640 medium containing 2.0 Mm L-glutamine, 10% fetal calf serum and 1% penicillin/streptomycin to obtain a concentration of 2 X 10 6 cells/mL.
  • Incubation A 0.1 mL portion of compound solution is added to the wells (3 wells for each treatment) of a 96 well round bottom tissue culture plate. Control wells receive 0.1 mL portions of medium. A 0.1 mL portion of cell suspension (I X IO 5 cells) is added to each well and the plates are incubated for 48 hours at 37°C in the presence of 5% carbon dioxide. During the last 4 to 6 hour of culture 1 Ci of 3 H-thymidine (having a specific activity of 6.7 Ci/mmole; available from New England Nuclear) is added to each well.
  • Cultures are harvested and collected on glass fiber filter strips. Each strip is placed in a scintillation vial. A 1 to 2 mL portion of Aquasol®-2 Universal LSC Cocktail (available from DuPont) is added to each well. After 15 minutes the radioactivity is counted for 1 minute in a scintillation counter. A stimulation index (SI) is calculated by dividing the counts per minute from the treatment wells by the counts per minute from the control wells. Results are shown in the table below.
  • SI stimulation index
  • Concentrations are the final concentrations found in the well after the addition of the cell suspension.
  • the CPM value is the mean CPM of the three wells for each treatment.
  • Phytohemagglutinin (PHA) and lipopolysaccharide (LPS) are included as reference agents.
  • Spleen Cell Preparation for Culture Spleens are aseptically removed from male CFW mice 4 to 8 weeks of age and placed in 10 mL of Hank's Balanced Salts Solution (HBSS) .
  • a scalpel is used to remove the cells from the capsule.
  • a single cell suspension is prepared by pipetting the suspension several times using a 5.0 mL syringe equipped with a 19 gauge needle. The suspension is transferred to a 15 mL centrifuge tube and allowed to stand on ice for 4 minutes. The supernatant is removed with a 10 mL pipet, transferred to a clean 15 mL centrifuge tube and centrifuged at 1200 rpm for 5 to 10 minutes. The supernatant is discarded.
  • the pellet is resuspended in 5 mL of 0.15M ammonium chloride, let stand at room temperature for 5 minutes and then centrifuged at 1200 rpm for 5 to 10 minutes. The supernatant is discarded.
  • the pellet is twice resuspended in 10 mL HBSS then centrifuged at 1200 rpm for 5 to 10 minutes. The supernatant is discarded.
  • the pellet is resuspended in RPMI 1640 medium containing 2.0 mM L-glutamine, 10% fetal calf serum, 1% penicillin/streptomycin and 5 X lO' 2- mercaptoethanol. The cells are counted then diluted with medium to give a concentration of 2 X IO 6 cells/mL.
  • Concanavalin A ConA
  • lipopolysaccharide LPS
  • staphylococcal enterotoxin B SEB
  • polyriboinosinic acid-polyribocytidylic acid Poly IC
  • the spleen cells are prepared as described above except that they are diluted in 6 well tissue culture plates to give a final concentration of 1 X IO 7 cells/mL.
  • the compounds are dissolved in water then diluted with medium to give the desired concentration.
  • a 0.1 mL portion of compound solution is added to each well (2 wells for each treatment) .
  • Control wells receive medium.
  • the final volume in the well is adjusted to 1 mL with medium.
  • the plates are incubated for 72 hours at 37°C in the presence of 5% carbon dioxide.
  • Antibody production is measured by utilizing a modified Jerne Plaque Assay. Briefly stated, the method is as follows. Plastic culture dishes are coated with 2 mL of poly-L-lysine (50 ⁇ g/mL) . After 15 minutes the plates are washed with phosphate buffered saline (PBS) and 2 mL of washed sheep red blood cells (SRBC) diluted 1:20 in PBS is added. After 15 minutes the plates are swirled, allowed to settle for another 15 minutes and rinsed with buffered saline. Finally, 1.5 mL of phosphate-buffered saline, pH 7.2, is added to each plate along with 2.5 X 10 5 spleen cells.
  • PBS phosphate buffered saline
  • SRBC washed sheep red blood cells
  • a stimulation index (SI) is calculated by dividing the PFC from the treatment wells by the PFC from the control (medium) wells.
  • Spleen Cell Preparation for Culture Spleen cells are prepared as described above in connection with the uptake of 3 H-thymidine.
  • the compounds are dissolved in water then diluted with medium to give the desired concentration. Incubation
  • a 0.9 mL portion of cell suspension is added to each well of a 12 well tissue culture plate.
  • a 0.1 mL portion of compound solution is added to the wells (2 wells for each treatment) .
  • Control wells receive 0.1 mL portions of medium. The plates are incubated for 72 hours at 37°C in the presence of 5% carbon dioxide.
  • the cell culture is removed from the well, combined with the culture from the second well, and washed twice with Hanks Balanced Salts Solution.
  • the cells are diluted with phosphate buffered saline (PBS) supplemented with 1% fetal calf serum (FCS) to give a concentration of 1 X 10 6 cells/100 ⁇ L.
  • the cells are stained with antibody for 30 minutes at 4°C.
  • Fluorescein isothiocyanate labeled goat anti-mouse immunoglobulin antibody (FITC ⁇ I G ) functions as the B cell marker.
  • Fluorescein isothiocyanate labeled anti mouse Thy 1.2 antibody functions as the T cell marker.
  • the cells are then washed twice with PBS supplemented with 1% FCS then analyzed for fluorescence using a Becton Dickinson FACSCAN. The results are reported as the percentage of the total cells, both the whole (unseparated) cells and the blast-like cells, that are positive for the marker.
  • the concentrations are the final concentrations in the well after both the cell suspension and the compound solution have been added. Lipopolysaccharide is included as a reference agent.
  • mice 4 to 8 weeks of age are injected intraperitoneally with sheep red blood cells (1 X 10 7 in phosphate buffered saline). Also on day 0, test compounds are dissolved in sterile water then injected intraperitoneally (3 mice for each treatment) . On day 4 the mice are sacrificed and the spleens are removed. Single cell suspensions are prepared in phosphate buffered saline to give a final concentration of 5 X 10 5 cells/mL for use in a modified Jerne Plaque Assay. The assay is performed as described above in connection with antibody formation in spleen cell cultures. The results are reported as plaque forming cells (PFC) per 10° cells and per spleen. A stimulation index (SI) is calculated by dividing the PFC value for the treatment group by the PFC value for the control (SRBC but no compound) group.
  • SI stimulation index
  • Results are shown in the table below. Values are the average number of plaque forming cells (PFC) 1 SEM. Each data point is the average of three mice pooled. Lipopolysaccharide (LPS) and polyriboinosinic acid- polyribocytidylic acid (Poly IC) are included as reference agents.
  • LPS Lipopolysaccharide
  • Poly IC polyriboinosinic acid- polyribocytidylic acid
  • HSV-2 (strain MS) infected Vero cells were solubilized and the glycoproteins were purified by lentil-lectin sepharose chromatography. The final preparation contained all three HSV-2 glycoproteins, gB, gD, and gG, that were evaluated. The glycoprotein preparation was diluted to contain 35 ⁇ g/0.1 mL total glycoprotein. Glycoprotein administration is described below in connection with the experimental design. Treatment Groups
  • 1-(2-methylpropyl)-lH-imidazo[4,5-c]quinolin-4- amine one percent by weight in a cream containing water (76.5%), isosteric acid (10%), stearyl alcohol (3.1%), polysorbate 60 (2.55%), cetyl alcohol (2.2%), benzyl alcohol (2%) , glycerin (2%) , sorbitan onostearate (0.45%), methylparaben (0.2%), and propylparaben (0.02%) was administered to guinea pigs as described below intravaginally at a concentration of 5 mg/kg/day for 5 days beginning either simultaneously with glycoprotein administration ("S group”) , or after a delay of 48h after glycoprotein administration (“D group”) .
  • S group glycoprotein administration
  • D group glycoprotein administration
  • hydrochloride salt was administered in water subcutaneously at a dose of 3 mg/kg/day for 5 days beginning simultaneously with glycoprotein administration ("subQ s group”).
  • Complete Freund's adjuvant (“CFA”, Sigma) was administered as a 1:1 mixture of the adjuvant and the glycoprotein (“CFA Group”) .
  • An unimmunized infected control group was maintained. Also one group was given the glycoprotein alone (“glycoprotein group”) .
  • Hartley female guinea pigs (Charles River Breeding Laboratory, Wilmington, Mass.) weighing 200-300 g were immunized with 35 ⁇ g of HSV-2 glycoproteins in the hind footpads, first 35 days prior to vaginal inoculation with HSV-2 and again 14 days prior to inoculation.
  • Enzyme-linked immunosorbent assay for HSV-2 antibodies HSV-2 antibodies were quantified by an ELISA assay. Lectin purified HSV-2 glycoproteins were used as the solid phase and peroxidase-conjugated rabbit anti- guinea pig immunoglobulins (Accurate Chemical, Westbury, N.Y.) were used for detection of guinea pig antibody. Absorbances were compared to a standardized control serum arbitrarily assigned a value of 10,000 ELISA units.
  • the recurrence pattern was similar for the unimmunized control group and glycoprotein group (4.9 i 0.9 vs. 4.3 1 0.9 recurrent lesion days, respectively).
  • the use of 1-(2-methylpropyl)-1H- imidazo[4,5-c3quinolin-4-amine as an adjuvant significantly reduced recurrent lesion days to 0.8 1 0.3 and 0.11 0.1, respectively, for the S Group and D Group (p ⁇ .01 for each compared to the glycoprotein group) .
  • Only one of ten animals in the S Group developed a recurrence, while eight of nine recipients of glycoprotein alone (p ⁇ .002) developed a recurrence.
  • Three of ten animals in the CFA Group developed recurrent lesions.
  • the only groups to develop lesions acutely were the unimmunized groups (Compound Group, 9 of 9; unimmunized control group, 11 of 11) and the glycoprotein group (6 of 11) . Again, because of the significant effect of immunization with glycoprotein alone, only small adjuvant effects of l-(2- methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine on the severity of the acute disease could be demonstrated (differences in total lesion score (p ⁇ .05) for each compared to glycoprotein alone) .
  • Vaginal viral shedding was also decreased by immunization with glycoprotein alone.
  • viral shedding was decreased tenfold in the D Group, by another tenfold in the S Group (p ⁇ .05), and by yet another tenfold in the SubQ s Group (p ⁇ .00i) on day one.
  • there was >99.9% reduction in the SubQ S Group compared to the glycoprotein group and a >99.9% reduction compared to the unimmunized control group.
  • No virus was detected in the CFA group.
  • Treatment with 1-(2-methylpropyl)-1H- imidazo[4,5-c]quinolin-4-amine alone had no significant effect on vaginal viral shedding.
  • Antibody titers in the CFA group were again over tenfold higher than the glycoprotein group (p ⁇ .001) and the D Group, S Group, and SubQ S Group (p ⁇ .01). Groups that received l-(2-methylpropyl)-lH-imidazo[4,5- c]quinolin-4-amine as an adjuvant did not, however, develop higher titers of HSV-2 antibody than the glycoprotein group. The Compound Group developed higher antibody titers than the unimmunized control group (p ⁇ .05) .
  • the most effective regimen involved subcutaneous administration for 5 doses beginning at the time of immunization. The results were comparable to using CFA as an adjuvant. Animals that received intravaginal administration had decreased viral titers and fewer recurrent lesion days. The addition of 1-(2-methylpropyl)-lH-imidazo[4,5- c]guinolin-4-amine to glycoprotein immunization had little effect on antibody titers but significantly increased the protection provided by the glycoprotein preparation especially against recurrent disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/US1993/003295 1992-04-16 1993-04-08 Vaccine adjuvant WO1993020847A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU40480/93A AU674313B2 (en) 1992-04-16 1993-04-08 Vaccine adjuvant
KR1019940703651A KR100263804B1 (ko) 1992-04-16 1993-04-08 백신 보강제
NZ280098A NZ280098A (en) 1992-04-16 1993-04-08 Potentiation of immune response using an 1h-imidazo [4,5-c]quinoline-4-amine as adjuvant
JP51846793A JP3732506B2 (ja) 1992-04-16 1993-04-08 ワクチンアジュバント
DE69304521T DE69304521T2 (de) 1992-04-16 1993-04-08 Impfstoff Adjuvans
CA002118239A CA2118239C (en) 1992-04-16 1993-04-08 1h-imidazo{4,5-c}quinolin-4-amines as vaccine adjuvants
EP93911614A EP0636031B1 (en) 1992-04-16 1993-04-08 Vaccine adjuvant
HK98107214A HK1007962A1 (en) 1992-04-16 1993-04-08 Vaccine adjuvant
NO19943920A NO313864B1 (no) 1992-04-16 1994-10-14 Vaksineadjuvans

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86938692A 1992-04-16 1992-04-16
US07/869,386 1992-04-16

Publications (1)

Publication Number Publication Date
WO1993020847A1 true WO1993020847A1 (en) 1993-10-28

Family

ID=25353454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/003295 WO1993020847A1 (en) 1992-04-16 1993-04-08 Vaccine adjuvant

Country Status (18)

Country Link
US (1) US6083505A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0636031B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3732506B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100263804B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE142110T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU674313B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2118239C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69304521T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0636031T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2092306T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1007962A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU217209B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL105325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9302199A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO313864B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ252020A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1993020847A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA932627B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039969A (en) * 1996-10-25 2000-03-21 3M Innovative Properties Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
WO2000047719A3 (en) * 1999-02-11 2000-11-30 3M Innovative Properties Co Maturation of dendritic cells with immune response modifying compounds
WO2001074343A3 (en) * 2000-03-30 2002-02-07 3M Innovative Properties Co Method for the treatment of dermal lesions caused by envenomation
WO2002022125A1 (en) * 2000-09-15 2002-03-21 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
WO2002024225A1 (en) * 2000-09-20 2002-03-28 Glaxo Group Limited Use of immidazoquinolinamines as adjuvants in dna vaccination
WO2003080114A3 (en) * 2002-03-19 2003-11-06 Powderject Res Ltd Imidazoquinoline adjuvants for vaccines
WO2003080112A3 (en) * 2002-03-19 2003-11-06 Powderject Res Ltd Imidazoquinolineamines as adjuvants in hiv dna vaccination
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10039753B2 (en) 2015-09-14 2018-08-07 Pfizer Inc. Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
US10071051B2 (en) 2013-02-05 2018-09-11 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
US10195258B2 (en) 2013-02-05 2019-02-05 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
US10206985B2 (en) 2013-02-05 2019-02-19 Nitto Denko Corporation WT1 peptide cancer vaccine composition for mucosal administration
US10449144B2 (en) 2013-02-05 2019-10-22 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
CA2330610A1 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
AU2002232498B2 (en) * 2000-12-08 2006-05-04 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
CA2458876A1 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
ATE416771T1 (de) * 2001-11-16 2008-12-15 3M Innovative Properties Co N-ä4-(4-amino-2-ethyl-1h-imidazoä4,5-cüchinolin 1-yl)butylümethanesulfonamide, diese enthaltende pharmazeutische zusammensetzung und deren verwendung
MXPA04005023A (es) * 2001-11-29 2004-08-11 3M Innovative Properties Co Formulaciones farmaceuticas que comprenden un modificador de respuesta inmune.
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7030129B2 (en) * 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
US20030185835A1 (en) * 2002-03-19 2003-10-02 Braun Ralph P. Adjuvant for vaccines
GB0206461D0 (en) * 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2003103584A2 (en) * 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
AU2003299863B2 (en) 2002-08-15 2009-09-24 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
JP2006503068A (ja) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
EP1590348A1 (en) 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
JP2006519866A (ja) 2003-03-04 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー Ｕｖ誘発性の表皮の新形成の予防的治療
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
KR20050107497A (ko) * 2003-03-07 2005-11-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 1-아미노 1ｈ-이미다조퀴놀린
CA2518445A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
AU2004220466A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
CN100558361C (zh) * 2003-03-13 2009-11-11 3M创新有限公司 改善皮肤质量的方法
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
AU2004229478B2 (en) * 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
KR20060054371A (ko) * 2003-07-31 2006-05-22 쓰리엠 이노베이티브 프로퍼티즈 컴파니 캡슐화 및 제어된 방출을 위한 조성물
US8221771B2 (en) * 2003-08-05 2012-07-17 3M Innovative Properties Company Formulations containing an immune response modifier
AU2004266641A1 (en) * 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
AU2004266657B2 (en) * 2003-08-14 2009-07-02 3M Innovative Properties Company Lipid-modified immune response modifiers
AU2004266162A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
WO2005020912A2 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
ES2406730T3 (es) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
WO2005020995A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
JP2007505629A (ja) * 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ遺伝子発現の選択的調節
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
CA2543685A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CA2545774A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
JP2007511535A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
EP1686992A4 (en) * 2003-11-25 2009-11-04 3M Innovative Properties Co HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
JP2007513170A (ja) * 2003-12-04 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー スルホン置換イミダゾ環エーテル
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
AU2004312510A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
US20070167479A1 (en) * 2004-03-15 2007-07-19 Busch Terri F Immune response modifier formulations and methods
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
AU2005244260B2 (en) * 2004-04-09 2010-08-05 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
JP2008505857A (ja) * 2004-04-28 2008-02-28 スリーエム イノベイティブ プロパティズ カンパニー 粘膜ワクチン接種のための組成物および方法
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006026470A2 (en) * 2004-08-27 2006-03-09 3M Innovative Properties Company Hiv immunostimulatory compositions
WO2006029115A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
EP1789042B1 (en) * 2004-09-02 2012-05-02 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP2008526751A (ja) * 2004-12-30 2008-07-24 武田薬品工業株式会社 １−（２−メチルプロピル）−１ｈ−イミダゾ［４，５−ｃ］［１，５］ナフチリジン−４−アミンエタンスルホナート及び１−（２−メチルプロピル）−１ｈ−イミダゾ［４，５−ｃ］［１，５］ナフチリジン−４−アミンメタンスルホナート
WO2006074003A2 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006074045A2 (en) * 2004-12-30 2006-07-13 3M Innovative Properties Company Immune response modifier formulations and methods
AU2005321912B2 (en) * 2004-12-30 2012-04-05 3M Innovative Properties Company Treatment for cutaneous metastases
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006091394A2 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
ES2569654T3 (es) 2005-02-18 2016-05-12 Glaxosmithkline Biologicals Sa Proteínas y ácidos nucleicos de la meningitis / sepsis asociada a la Escherichia coli
WO2006098852A2 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
US8846710B2 (en) 2005-02-23 2014-09-30 3M Innovative Properties Company Method of preferentially inducing the biosynthesis of interferon
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2006091568A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
CN101175493A (zh) 2005-03-14 2008-05-07 3M创新有限公司 治疗光化性角化病的方法
JP2008538550A (ja) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ，インコーポレイテッド ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
US20100017895A1 (en) 2005-07-18 2010-01-21 Amy Weiner Small animal model for hcv replication
CA2621831A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
JP5247458B2 (ja) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2640248A1 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Influenza vaccines containing hemagglutinin and matrix proteins
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
DE102006015585A1 (de) * 2006-04-04 2007-10-18 Mahle International Gmbh Kolben für einen Verbrennungsmotor
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
AU2006342608A1 (en) * 2006-04-25 2007-11-01 Intercell Ag HCV vaccinations
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
JP5954921B2 (ja) 2006-09-11 2016-07-20 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US20090074828A1 (en) * 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
CN101784655A (zh) * 2007-04-27 2010-07-21 菲尼克斯股份有限公司 可溶性重组二十面体病毒样颗粒的改良生成和体内装配
ES2393162T3 (es) 2007-06-27 2012-12-19 Novartis Ag Vacunas antigripales con un contenido reducido de aditivos
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2394657A1 (en) 2007-10-12 2011-12-14 Massachusetts Institute Of Technology Vaccine nanotechnology
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2009210655B2 (en) * 2008-02-07 2013-08-15 Telormedix Sa Treatment of bladder diseases with a TLR7 activator
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
JP5781932B2 (ja) 2008-11-03 2015-09-24 アレシア・バイオセラピューティクス・インコーポレーテッド 腫瘍抗原の生物活性を特異的にブロックする抗体
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
MX2011010735A (es) 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
CA2763816A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
RU2585227C2 (ru) 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
US8871214B2 (en) 2009-07-16 2014-10-28 Novartis Ag Detoxified Escherichia coli immunogens
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
MX2012013715A (es) 2010-05-26 2013-01-28 Selecta Biosciences Inc Seleccion de dosis de nanovehiculos sinteticos con adyuvante.
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP2606047B1 (en) 2010-08-17 2017-01-25 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
SI2667892T1 (sl) 2011-01-26 2019-05-31 Glaxosmithkline Biologicals Sa Imunizacijski režim proti RSV
HUE045943T2 (hu) 2011-03-31 2020-02-28 Adc Therapeutics Sa Veseasszociált antigén 1 és antigénkötõ fragmensei elleni antitestek
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
AU2012261959B2 (en) 2011-06-03 2015-12-03 Solventum Intellectual Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
MX347240B (es) 2011-06-03 2017-04-20 3M Innovative Properties Co Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
SI2794627T1 (sl) 2011-12-22 2019-02-28 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
EA034414B1 (ru) 2012-01-09 2020-02-05 Адс Терапьютикс Са Способ лечения тройного негативного рака молочной железы
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX376234B (es) 2012-05-04 2025-03-07 Pfizer Anticuerpo anti-ctla-4 como modulador inmune.
US20140220058A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
CN103961306A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
US20140220100A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
RU2014102941A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для введения через слизистую оболочку
IN2014CH00386A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-02-05 2015-04-03 Nitto Denko Corp
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
WO2015144655A1 (en) 2014-03-26 2015-10-01 Glaxosmithkline Biologicals S.A. Immunising against staphylococcus aureus
JP7197244B2 (ja) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ［４，５－ｃ］キノリン化合物
EP4146204A4 (en) * 2020-05-05 2024-07-03 Virovax LLC Vaccine adjuvants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0145340A2 (en) * 1983-11-18 1985-06-19 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines
EP0385630A2 (en) * 1989-02-27 1990-09-05 Riker Laboratories, Inc. 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals
EP0389302A1 (en) * 1989-03-23 1990-09-26 Riker Laboratories, Inc. Olefinic 1H-imidazo [4,5-c]quinolin-4-amines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4716168A (en) * 1985-01-08 1987-12-29 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4619827A (en) * 1985-10-07 1986-10-28 Neogen Corporation Method for administering equine vaccines and compositions therefor
US4689224A (en) * 1985-10-07 1987-08-25 Neogen Corporation Method for administering vaccines containing equine leukokines and compositions therefor
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
EP0273512B1 (en) * 1986-12-19 1991-02-27 Duphar International Research B.V Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
ES2052685T3 (es) * 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US5015476A (en) * 1989-08-11 1991-05-14 Paravax, Inc. Immunization implant and method
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0145340A2 (en) * 1983-11-18 1985-06-19 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines
EP0385630A2 (en) * 1989-02-27 1990-09-05 Riker Laboratories, Inc. 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals
EP0389302A1 (en) * 1989-03-23 1990-09-26 Riker Laboratories, Inc. Olefinic 1H-imidazo [4,5-c]quinolin-4-amines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY vol. 33, no. 9, September 1989, pages 1511 - 1515 DAVID I. BERNSTEIN ET AL. THE WHOLE ARTICLE *
ANTIVIRAL RESEARCH vol. 10, 1988, pages 209 - 223 C.J. HARRISON ET AL. THE WHOLE ARTICLE *
THE JOURNAL OF INFECTIOUS DISEASES vol. 167, no. 3, March 1993, pages 731 - 735 DAVID I. BERNSTEIN ET AL. 'ADJUVANT EFFECTS OF IMIQUIMOD ON A HERPES SIMPLEX VIRUS TYPE 2 GLYCOPROTEIN VACCINE IN GUINEA PIGS.' THE WHOLE ARTICLE *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696076B2 (en) 1996-10-25 2004-02-24 3M Innovative Properties Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
US6200592B1 (en) 1996-10-25 2001-03-13 3M Innovative Properties Company Immine response modifier compounds for treatment of TH2 mediated and related diseases
US6039969A (en) * 1996-10-25 2000-03-21 3M Innovative Properties Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
US6610319B2 (en) 1996-10-25 2003-08-26 3M Innovative Properties Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
WO2000047719A3 (en) * 1999-02-11 2000-11-30 3M Innovative Properties Co Maturation of dendritic cells with immune response modifying compounds
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
WO2001074343A3 (en) * 2000-03-30 2002-02-07 3M Innovative Properties Co Method for the treatment of dermal lesions caused by envenomation
AU2001251146B2 (en) * 2000-03-30 2004-12-16 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
WO2002022125A1 (en) * 2000-09-15 2002-03-21 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
WO2002024225A1 (en) * 2000-09-20 2002-03-28 Glaxo Group Limited Use of immidazoquinolinamines as adjuvants in dna vaccination
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
WO2003080112A3 (en) * 2002-03-19 2003-11-06 Powderject Res Ltd Imidazoquinolineamines as adjuvants in hiv dna vaccination
WO2003080114A3 (en) * 2002-03-19 2003-11-06 Powderject Res Ltd Imidazoquinoline adjuvants for vaccines
AU2003216851B2 (en) * 2002-03-19 2008-04-17 Powderject Research Limited Imidazoquinoline adjuvants for vaccines
AU2003216852B2 (en) * 2002-03-19 2008-09-11 Glaxo Group Limited Imidazoquinolineamines as adjuvants in HIV DNA vaccination
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US10071051B2 (en) 2013-02-05 2018-09-11 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
US10195258B2 (en) 2013-02-05 2019-02-05 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
US10206985B2 (en) 2013-02-05 2019-02-19 Nitto Denko Corporation WT1 peptide cancer vaccine composition for mucosal administration
US10449144B2 (en) 2013-02-05 2019-10-22 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10039753B2 (en) 2015-09-14 2018-08-07 Pfizer Inc. Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Also Published As

Publication number Publication date
HUT69993A (en) 1995-09-28
KR100263804B1 (ko) 2000-08-16
HU211298A9 (en) 1995-11-28
JP2004043496A (ja) 2004-02-12
NO313864B1 (no) 2002-12-16
HU9402978D0 (en) 1995-02-28
ATE142110T1 (de) 1996-09-15
JP3732506B2 (ja) 2006-01-05
DE69304521D1 (de) 1996-10-10
DK0636031T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-02-24
NZ252020A (en) 1995-12-21
IL105325A0 (en) 1993-08-18
EP0636031B1 (en) 1996-09-04
NO943920L (no) 1994-10-14
AU674313B2 (en) 1996-12-19
MX9302199A (es) 1994-08-31
IL105325A (en) 1996-11-14
AU4048093A (en) 1993-11-18
US6083505A (en) 2000-07-04
EP0636031A1 (en) 1995-02-01
HU217209B (hu) 1999-12-28
CA2118239A1 (en) 1993-10-28
CA2118239C (en) 2009-04-07
ZA932627B (en) 1994-10-14
NZ280098A (en) 1998-06-26
DE69304521T2 (de) 1997-02-20
ES2092306T3 (es) 1996-11-16
JPH07505883A (ja) 1995-06-29
HK1007962A1 (en) 1999-04-30
NO943920D0 (no) 1994-10-14

Similar Documents

Publication Publication Date Title
US6083505A (en) 1H-imidazo[4,5-C]quinolin-4-amines as vaccine adjuvants
HK1007962B (en) Vaccine adjuvant
Emmings et al. Antibody response in the parotid fluid and serum of Irus monkeys (Macaca fascicularis) after local immunization with Streptococcus mutans
Cong et al. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii
Bouzoubaa et al. Use of membrane proteins from Salmonella gallinarum for prevention of fowl typhoid infection in chickens
FUKUDA et al. Vaccination of yellowtail against pseudotuberculosis
US6368599B1 (en) Caulobacter LPS immunoadjuvants
EP1768696B1 (en) Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
AU711915B2 (en) Plasmid vaccine against pseudorabies virus
Chen et al. Immunization against" Brucella" Infections: Immune Response of Mice, Guinea pigs, and Cynomolgus philipinensis to Live and Killed Brucella melitensis Strain Rev. I Administered by Various Methods
Norrby et al. Humoral immunity to canine distemper after immunization of dogs with inactivated and live measles virus
AU607130B2 (en) Improvements in and relating to vaccines
Fukuda et al. Acquired antibody against pseudotuberculosis in yellowtail
US6905712B2 (en) Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
Tremonti et al. Study of delayed hypersensitivity to myxoviruses induced by vaccines
KR20140060053A (ko) 인플루엔자 백신용 면역증강제
Lazàry et al. Immune response to haemophilus parahaemolyticus (HP) infection in the pig I. In vitro tests to detect sensitized cells in the blood of infected and vaccinated animals
CN118108815B (zh) 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用
Hofman et al. Phenol—water extracts of gram-positive listeria monocy togenes and gram-negative salmonella typhimurium. comparison of biological activities
Jenkins et al. Effect of levamisole on parenteral vaccines for swine dysentery
Abdel-Khalek et al. Effect of propionobacterium and E. Coli lipopolysaccharide (inmunair 17.5) immunomodulator on response of rabbits to RHDV vaccine
Frankenburg et al. Cell-mediated responses and protection elicited by a carbohydrate-lipid-containing fraction extracted from Leishmania major promastigotes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 252020

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1993911614

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2118239

Country of ref document: CA

Ref document number: 1019940703651

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1993911614

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1993911614

Country of ref document: EP